LocoMMotion:复发和/或难治性多发性骨髓瘤患者真实世界当前标准治疗的前瞻性、非干预性、多国研究
LocoMMotion是首个在既往暴露于蛋白酶体抑制剂、免疫调节药物和抗CD38单克隆抗体的复发/难治性多发性骨髓瘤患者中开展的真实世界标准治疗前瞻性研究。248例患者接受中位4.0个周期标准治疗,总缓解率29.8%,中位无进展生存期4.6个月,中位总生存期12.4个月。共使用92种不同方案,提示该人群缺乏明确标准治疗且结局不佳。
要点
- 三重暴露复发/难治性骨髓瘤患者真实世界总缓解率为29.8%(95%CI 24.2-36.0)。
- 中位无进展生存期4.6个月(95%CI 3.9-5.6),中位总生存期12.4个月(95%CI 10.3-未达)。
- 共使用92种不同方案,提示该人群缺乏明确标准治疗。
核心结论
- 真实世界实践中三重暴露复发/难治性多发性骨髓瘤患者缺乏明确标准治疗,结局不佳,支持需要具有新作用机制的新治疗。
研究设计与样本
- LocoMMotion(NCT04035226)是首个在真实世界标准治疗下开展的前瞻性、非干预性、多国研究。
- 纳入248例复发/难治性多发性骨髓瘤患者,要求ECOG体能状态0-1、既往≥3线治疗或对蛋白酶体抑制剂和免疫调节药物双重难治,且既往暴露于蛋白酶体抑制剂、免疫调节药物和抗CD38单克隆抗体。
主要发现
- 患者接受中位4.0(范围1-20)个周期的标准治疗。
- 总缓解率为29.8%(95%CI 24.2-36.0)。
- 中位无进展生存期为4.6个月(95%CI 3.9-5.6),中位总生存期为12.4个月(95%CI 10.3-未达)。
- 治疗中出现的不良事件发生于83.5%的患者,其中52.8%为3/4级。
- 共发生107例死亡,死于疾病进展74例、治疗中出现的不良事件19例、其他原因14例。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite treatment advances, patients with multiple myeloma (MM) often progress through standard drug classes including proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), and anti-CD38 monoclonal antibodies (mAbs). LocoMMotion (ClinicalTrials.gov identifier: NCT04035226) is the first prospective study of real-life standard of care (SOC) in triple-class exposed (received at least a PI, IMiD, and anti-CD38 mAb) patients with relapsed/refractory MM (RRMM). Patients (N = 248; ECOG performance status of 0-1, ≥3 prior lines of therapy or double refractory to a PI and IMiD) were treated with median 4.0 (range, 1-20) cycles of SOC therapy. Overall response rate was 29.8% (95% CI: 24.2-36.0). Median progression-free survival (PFS) and median overall survival (OS) were 4.6 (95% CI: 3.9-5.6) and 12.4 months (95% CI: 10.3-NE). Treatment-emergent adverse events (TEAEs) were reported in 83.5% of patients (52.8% grade 3/4). Altogether, 107 deaths occurred, due to progressive disease (n = 74), TEAEs (n = 19), and other reasons (n = 14). The 92 varied regimens utilized demonstrate a lack of clear SOC for heavily pretreated, triple-class exposed patients with RRMM in real-world practice and result in poor outcomes. This supports a need for new treatments with novel mechanisms of action.
引用
- Mateos MV, Weisel K, De Stefano V, et al. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma. Leukemia. 2022. PMID: 35332278. doi:10.1038/s41375-022-01531-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。